Table 1.
Baseline demographic data and clinical characteristics of 117 patients with an initial indication for NIPPV support.
| Group A (n = 96) | Group B (n = 13) | Group C (n = 8) | |
|---|---|---|---|
| Male | 49 (51) | 7 (54) | 5 (50) |
| Age, yrs | 68 (37–85) | 61 (56–78) | 67 (54–80) |
| Lung function | |||
| FEV1, L | 0.81 (0.39–2.34) | 0.65 (0.54–2.20) | 1.04 (0.77–1.58)*,† |
| FEV1, %pred | 35 ± 13 | 34 ± 15 | 43 ± 4 |
| FVC, L | 1.85 (0.93–3.59) | 1.45 (1.41–3.54) | 1.78 (1.03–2.52) |
| FVC, %pred | 59 (26–86) | 53 (39–79) | 61 (21–68) |
| FEV1/FVC | 0.46 ± 0.10 | 0.45 ± 0.86 | 0.64 ± 0.05*,† |
| GOLD classification | |||
| Moderate (II) | 19 (20) | 1 (8) | 1 (13) |
| Severe (III) | 51 (53) | 5 (38) | 5 (62) |
| Very severe (IV) | 26 (27) | 7 (54) | 2 (25) |
| Comorbid conditions | |||
| Hypertension | 57 (59) | 8 (62) | 6 (75) |
| Ex-smoker | 56 (58) | 7 (54) | 5 (62) |
| Active smoking | 16 (17) | 4 (31) | 2 (25) |
| Diabetes mellitus | 23 (24) | 6 (46) | 3 (38) |
| Heart failure | 19 (20) | 2 (15) | 3 (38) |
| Manchester risk classificationa | |||
| Immediate | 17 (18) | – | 2 (25) |
| Very urgent | 66 (69) | 13 (100) | 5 (62) |
| Urgent | 5 (5) | – | 1 (13) |
| Home NIPPV use | 5 (5) | 0 (0) | 0 (0) |
| Home oxygen therapy | 42 (44) | 3 (23) | 1 (13) |
Values are presented as mean ± SD or median (minimum–maximum), and absolute number (frequency %). Definition of abbreviations: NIPPV, noninvasive positive pressure ventilation; FEV1, forced expiratory volume in 1 s; %pred, percent of predicted; FVC, forced vital capacity.
*
p < 0.05 between Group A and Group C.
†
p < 0.05 between Group B and Group C.
a
n = 88.